SCHEMBL798035

SCHEMBL798035

CCOC(=O)Cn1ncc(-c2nc(-c3cc(F)ccc3F)no2)c1-c1ccccc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 10/20 1.00
SMN1; SMN2 Q16637 3/20 0.48
TSHR P16473 1/20 0.43
NPSR1 Q6W5P4 2/20 0.41
LMNA P02545 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
GAA P10253 1/20 0.41
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
MAOA P21397 1/20 0.40
BLVRB P30043 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL797415 0.92 S1PR1 (0.85) S1PR1SMN1; SMN2GAA
SCHEMBL15929388 0.88 S1PR1 (0.78) S1PR1SMN1; SMN2L3MBTL1MEN1KMT2A
SCHEMBL773443 0.84 S1PR1 (0.80) S1PR1SMN1; SMN2L3MBTL1GAAMEN1
SCHEMBL13049383 0.82 S1PR1 (0.70) S1PR1SMN1; SMN2TSHRNPSR1L3MBTL1
SCHEMBL773462 0.82 S1PR1 (0.76) S1PR1SMN1; SMN2L3MBTL1MEN1KMT2A
SCHEMBL772797 0.81 S1PR1 (0.69) S1PR1SMN1; SMN2L3MBTL1MEN1KMT2A
SCHEMBL772453 0.81 S1PR1 (1.00) S1PR1SMN1; SMN2L3MBTL1GAAMEN1
SCHEMBL15929389 0.81 S1PR1 (0.73) S1PR1KMT2AMAOABLVRBHDAC6
SCHEMBL772887 0.80 S1PR1 (0.67) S1PR1SMN1; SMN2L3MBTL1MEN1KMT2A
SCHEMBL9877275 0.80 SMN1; SMN2 (0.67) S1PR1SMN1; SMN2TSHRNPSR1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2440554-B1 PYRAZOLE OXADIAZOLE DERIVATIVES AS S1P1 AGONISTS MERCK SERONO SA (CH) 2016-10-05 EP disclosed
US-8802663-B2 Pyrazole oxadiazole derivatives as S1P1 agonists MERCK SERONO SA (CH) 2014-08-12 US disclosed
US-8802663-B2 Pyrazole oxadiazole derivatives as S1P1 agonists MERCK SERONO SA (CH) 2014-08-12 US disclosed
US-20120071460-A1 PYRAZOLE OXADIAZOLE DERIVATIVES AS S1P1 AGONISTS MERCK SERONO SA (CH) 2012-03-22 US disclosed
US-20120071460-A1 PYRAZOLE OXADIAZOLE DERIVATIVES AS S1P1 AGONISTS MERCK SERONO SA (CH) 2012-03-22 US disclosed
WO-2010142628-A1 PYRAZOLE OXADIAZOLE DERIVATIVES AS S1P1 AGONISTS MERCK SERONO S.A. (CH) 2010-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071460-A1 PYRAZOLE OXADIAZOLE DERIVATIVES AS S1P1 AGONISTS S1PR1, S1PR3, S1PR2 S1PR1 1/4885SMN1; SMN2 895/4885TSHR 435/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.